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Abstract 
The luminal A phenotype is the most common breast cancer subtype and is characterized by estrogen 
receptor α expression (ERα). Identification of the key regulator that governs the luminal phenotype of breast 
cancer will clarify the pathogenic mechanism and provide novel therapeutic strategies for this subtype of 
cancer. ERα signaling pathway sustains the epithelial phenotype and inhibits the epithelial-mesenchymal 
transition (EMT) of breast cancer. In this study, we demonstrate that Notch3 positively associates with ERα 
in both breast cancer cell lines and human breast cancer tissues. We found that overexpression of Notch3 
intra-cellular domain, a Notch3 active form (N3ICD), in ERα negative breast cancer cells re-activated ERα, 
while knock-down of Notch3 reduced ERα transcript and proteins, with alteration of down-stream genes, 
suggesting its ability to regulate ERα. Mechanistically, our results show that Notch3 specifically binds to the 
CSL binding element of the ERα promoter and activates ERα expression. Moreover, Notch3 suppressed 
EMT, while suppression of Notch3 promoted EMT in cellular assay. Overexpressing N3ICD in triple-negative 
breast cancer suppressed tumorigenesis and metastasis in vivo. Conversely, depletion of Notch3 in luminal 
breast cancer promoted metastasis in vivo. Furthermore, Notch3 transcripts were significantly associated with 
prolonged relapse-free survival in breast cancer, in particular in ERα positive breast cancer patients. Our 
observations demonstrate that Notch3 governs the luminal phenotype via trans-activating ERα expression in 
breast cancer. These findings delineate the role of a Notch3/ERα axis in maintaining the luminal phenotype 
and inhibiting tumorigenesis and metastasis in breast cancer, providing a novel strategy to re-sensitize ERα 
negative or low-expressing breast cancers to hormone therapy. 
Key words: Notch3, estrogen receptor α, epithelial-mesenchymal transition, breast cancer, luminal phenotype. 
Introduction 
The majority of breast cancer deaths result from 
metastasis at distant sites [1]. One of the pivotal 
processes that induces tumor metastasis is conversion 
of epithelial cells to a mesenchymal phenotype, or the 
epithelial-mesenchymal transition (EMT) [2]. ERα, a 
typical marker of the luminal epithelial phenotype in 
breast cancer cells, is a good indicator of breast 
cancers that respond to endocrine therapy. E2/ERα 
signaling promotes the differentiation of mammary 









through transcriptional activation of luminal/ 
epithelial-related transcription factors [3]. For instance, 
in ERα positive breast cancer cells, knockdown of ERα 
decreased expression of the luminal epithelial marker 
E-cadherin and promoted invasion and motility [4-7]. 
ERα is thought to inhibit invasion by repressing Slug 
transcription and by phosphorylating and 
inactivating GSK-3β [4]. Thus, loss of ERα could 
promote metastasis of breast cancer cells [8, 9]. 
However, the mechanisms that regulate ERα in breast 
cancer cells are still poorly understood. Thus, 
elucidating the regulatory mechanisms of ERα may 
aid in understanding breast cancer metastasis and 
facilitate development of novel targets for breast 
cancer therapy.  
Notch family members play a critical role in the 
tumorigenesis and metastasis of breast cancers, and 
development of therapeutic agents that target the key 
steps in the Notch signaling pathway may provide 
strategies to inhibit tumor growth [10]. Increasing 
evidence demonstrates that Notch family proteins 
have distinct activities and biological functions [11]. 
Hao et al. demonstrated that Notch1 promotes growth 
of ERα-positive breast cancer [12]. Harrison et al. 
showed that Notch4 and Notch1 enhance breast 
cancer stem cell activity, and inhibition of Notch4 or 
Notch1 reduces tumor formation in vivo [13]. Yen et al. 
confirmed that suppression of Notch2/Notch3 
inhibits tumor growth and reduces the number of 
stem cells in breast, lung, ovarian, and pancreatic 
cancers [14-16].  
Little is known about Notch3’s potential roles in 
cancer development. Bouras et al. found that Notch3 
levels are specifically elevated in mouse mammary 
luminal progenitor and epithelial cells, but not in 
mammary stem cells [17], and similar results were 
also reported by transcriptome analysis [18]. In 
transformed breast cells, Notch3 is required for breast 
luminal filling by inhibiting apoptosis [19]. In 
transgenic mice, Notch3 promotes lobular-alveolar 
epithelial cell expansion and leads to tumor formation 
[20]. As ERα promotes mammary luminal/epithelial 
cell differentiation [3], these results suggest a close 
correlation between Notch3 and ERα expression in 
the luminal epithelial differentiation during breast 
development and breast cancer. However, Notch3 has 
been shown to play different or even opposing roles 
in modulating EMT in various cancers. For example, 
Notch3 induces EMT and promotes metastasis and 
invasion in glioma, hepatocellular carcinoma and 
ovarian cancer cells [21-23]. In contrast, Notch3 was 
shown to promote glandular differentiation and 
squamous differentiation in gastric and esophageal 
cancers, respectively, and reverses EMT or promotes 
mesenchymal epithelial transition (MET) [24, 25]. 
Recently, our group showed that Notch3 inhibits cell 
cycle progression by inducing Cdh1 and suppresses 
EMT through activating Kibra-mediated Hippo/YAP 
signaling in breast cancer epithelial cells [26,27], 
suggesting Notch3’s role in tumorigenesis and 
metastasis in breast cancers.  
These collective findings prompted us to 
investigate the role of Notch3 in tumorigenesis/ 
metastasis and ERα regulation of breast cancer, 
particularly its relationship to molecular subtypes of 
breast cancer. In this study, we investigated the 
regulatory mechanisms of EMT via Notch3 and ERα 
expressions in breast cancer.  
Materials and Methods  
Cell culture and transfection 
MCF-7, T47D, SKBR3, BT-549 and MDA-MB-231 
cell lines were obtained from the American Type 
Tissue Collection and cultured in DMEM medium 
supplemented with 10% FCS and 
penicillin/streptomycin. For Notch3 knockdown in 
MCF-7 cells, siRNAs targeting Notch3 and control 
siRNAs were synthesized by GenePharma (Suzhou, 
China). Oligonucleotide siRNAs are listed in 
Supplementary Table S2. For Notch3 overexpression 
in MDA-MB-231 cells, pCLE-N3ICD (Plasmid 26894) 
and control vector pCLE (Plasmid 17703) were 
obtained from Addgene (MA, USA). A stable 
Notch3-silenced cell line, MCF-7shN3, was generated 
by transfection of pGPU6/GFP/Neo-shNotch3#1 
containing oligonucleotides specifically targeting 
Notch3, while its control cell line was also established 
with vector containing scramble sequence (see 
Supplementary Table S2) (GenePharma, Suzhou, 
China). A stable Notch3 ICD over-expressing cell line, 
MDA-MB-231-N3ICD, was generated by transfection 
of the pCLE-N3ICD vector. Lipofectamine 2000 was 
used for transfection according to the manufacturer’s 
instructions. To establish stable MCF-7-shN3 and 
MDA-MB-231-N3ICD cell lines, 1 μg/mL of G418 was 
added to the medium, for selection, 2 days following 
transfection.  
RNA purification and real-time PCR analysis 
RNA purification and cDNA synthesis were 
performed using Takara kits according to the 
manufacturer’s instructions. To detect mRNA 
expression, quantitative real-time PCR was 
performed with SYBR Select Master Mix (Thermo 
Fisher, MA, USA) and the CFX96 Real-time PCR 
Detection System (Bio-Rad, CA, USA). Primer 
sequences used in real-time PCR are listed in 
Supplementary Table S2. 





Western blot analysis 
Protein extraction and western blot were 
performed as described previously [28]. 
Characteristics of the antibodies used are listed in 
Supplementary Table S3. 
Immunofluorescence 
After 48 h of transfection, cells were fixed with 
4% paraformaldehyde for 10 min, then washed in cold 
PBS 3 times. Then, cells were permeabilized with 0.5% 
Triton-X-100 in PBS for 20 min. Cells were washed 
with cold PBS 3 times and blocked in 3% BSA in PBS 
for 1 h at room temperature and then incubated 
overnight at 4°C with primary antibody diluted in 
blocking buffer. After that, cells were washed with 
cold PBS 3 times and incubated with appropriate 
secondary antibodies (Alexa Fluor 594 Donkey 
Anti-Rabbit IgG, Alexa Fluor 488 Donkey Anti-Mouse 
IgG). Cells were washed again in PBS 3 times, and 
counterstained for 10 min with DAPI (Life, USA). 
Images were visualized with an inverted microscope. 
IHC and scoring 
Tissue sample processing and immunohisto-
chemistry were performed as previously described 
[29]. Briefly, the sample was processed by 
deparaffinization, rehydration, antigen retrieval, IHC 
staining and pathology scoring. Scores include the 
proportion of positive-staining tumor cells and 
staining intensities. The proportion of positive tumor 
cells were given scores of 0 (no tumor cells stained), 1 
(<10%), 2 (10%-50%), or 3 (>50%). The intensity of 
staining was scored as 0 (no staining), 1 (light yellow), 
2 (yellow), or 3 (brown). The score of intensity × 
proportion was regarded as low expression (<3) and 
high expression (≥3). Interpretation of IHC results 
were evaluated by two independent observers. ERα 
was scored as negative (-) and positive (+) staining 
according to expression. The antibodies used in 
immunohistochemistry staining are listed in 
Supplementary Table S3. 
Wound healing assay 
Cells were pretreated with mitomycin C (25 
mg/mL) 30 min before a scratch wound was applied. 
The wound was made with a 2 mm-wide tip on cells 
plated in culture dishes at 90% confluency. After 
rinsing with PBS, cells were allowed to migrate in 
complete medium, and photographs were taken (×40) 
after 24 h (MDA-MB-231) or 48 h (MCF-7). An average 
of five random widths along the injury line were 
measured for quantitation. 
Transwell migration and invasion assay 
Cell culture inserts (8 μM pore size; BD) and 
Matrigel invasion chambers (BD) were used to 
perform migration and invasion assays, respectively. 
Transfected cells were serum-starved for 24 h and 
2×104 MDA-MB-231 cells or 5×104 MCF-7 cells in 
serum-free medium were inoculated in the upper 
chamber. Complete medium was added to the bottom 
chamber. Cells were stained with 0.1% crystal violet 
for migration assays at 48 h (MDA-MB-231) or 48 h 
(MCF-7) and 48 h (MDA-MB-231and MCF-7) for 
invasion assays. Each assay was performed in 
triplicate. The number of cells from 5 fields in each 
well was counted by two independent investigators. 
Transient transfection and dual-luciferase 
reporter assays 
The ERα promoter (-928 upstream of exon1 and 
extending to +72 bp) was cloned into the NheI/BglII 
sites of a luciferase reporter vector (Panomics, USA). 
The ERα promoter deletion constructs Δ2CSL (-928 to 
-389 bp upstream of exon1) and ΔCSL (-928 to -169 bp 
upstream of exon1) were engineered into the same 
reporter vector. Transfection was performed using 
Lipofectamine 2000 according to the manufacturer’s 
instructions. pRL-SV40 (Promega, WI, USA) was used 
as control vector to normalize transfection efficiency. 
To detect the influence of silenced or overexpressed 
Notch3 on ERα promoter activity, the ERα reporter 
construct or its deletion constructs were 
co-transfected into MCF-7 cells with siRNA or 
expression vectors. A dual luciferase reporter assay 
kit (Promega, WI, USA) was employed to detect 
luciferase activity. Results were obtained by dual 
luciferase reporter assay or BLI using a Xenogeny IVIS 
Kinetic system.  
Chromatin immunoprecipitation (ChIP) assay 
MCF-7 cells were cultured in a 100 mm dish to 
80% confluence. CHIP assays were performed as 
previously described [21]. Cell lysates were incubated 
with IgG (Santa Cruz Biotechnology) as an IP control 
or an antibody specific to Notch3 (CST). Cell lysates 
(10%) were used for input PCR amplification. The 
PCR reaction amplified the 239 bp (located -527∽-298 
bp, ERαP2) and 230 bp products (located -328∽-90bp, 
ERαP1) from the ERα promoter containing CSL 
binding elements (located -380∽-384 bp and 
-159∽-155 bp upstream of exon 1). A 243 bp PCR 
reaction product (located -628∽-386 bp), which was 
near the CSL binding elements, but did not contain 
them, was used as a negative control. Primers and 
antibodies used in ChIP assays are listed in 
Supplementary Tables S2 and S3, respectively. 
Electrophoretic mobility shift assay (EMSA) 
Nuclear extracts were obtained from MCF-7 
cells. Oligonucleotides containing CSL binding 





elements were used in EMSAs. EMSA was performed 
according to manufacturer’s instructions (Viagene, 
FL, USA). In competition assays, excessive amounts of 
unlabeled competitor were added 20 min before 
addition of the labeled probes. For the supershift 
assay, anti-Notch3 monoclonal antibody (2 μg, CST) 
was added and incubated at 4°C for 60 min. Probe 
sequences and mutated competitors used in EMSA 
are shown in Supplementary Tables S2.  
Tumor xenograft models 
All animal protocols were approved by the 
Animal Care and Use Committee of Shantou 
University Medical College (SUMC). We used 
6-week-old Nu/Nu female mice (purchased from 
Vital River, Beijing, China) for all the experiments. 
Briefly, MDA-MB-231NC-Fluc or MDA-MB- 
231N3ICD-Fluc cells were injected via the lateral tail 
vein (1×106 cells) or unilaterally injected into the 
fourth mammary fat pad (2×106 cells) of each mouse. 
Tumor growth was monitored by measuring the 
length and width of tumors twice a week. Tumor 
volumes were estimated using the formula: 
length×width2×0.5. The development of whole-body 
metastasis was monitored by an IVIS Kinetic imaging 
system (PerkinElmer, MA, USA) once every 3 days. 15 
min before imaging, mice were injected i.p. with 150 
mg/kg D-luciferin (PerkinElmer, MA, USA). Mice 
were euthanized after 31 days following vein tail 
injection, or 42 days following mammary fat pad 
injection. At the time of killing, organs were harvested 
and visualized by the IVIS Kinetic imaging system. 
Tumor xenografts, lungs and livers were excised, 
fixed in 4% paraformaldehyde and embedded in 
paraffin. HE staining and immunohistochemistry 
were performed for tumor phenotype or detection of 
Notch3, ERα, E-cadherin and vimentin expression. 
For MCF-7 cells, Nu/Nu female mice were 
anesthetized and 2×106 MCF-7shNC or MCF-7shN3 
cells were injected via the tail vein. Mice were 
euthanized after 8 weeks. Lungs and livers were 
excised and fixed in 4% paraformaldehyde and 
embedded in paraffin. H&E staining was performed 
on the harvested organs. Tumor formation was 
identified by experts of the Department of Pathology 
in the Cancer Hospital of SUMC.  
Kaplan Meier analysis of Notch3 expression in 
breast cancer patients  
A publicly accessible online clinical database 
(http://kmplot.com) was used to assess the 
association between Notch3 expression and 
recurrence-free survival information in 4142 breast 
cancer patients [30, 31]. Kaplan-Meier survival curves, 
Hazard ratio (HR), 95 % confidence intervals and 
log-rank P were calculated and displayed on the 
webpage according to Notch3 expression status. 
Statistical analysis 
All experiments were performed in triplicate. 
Data are shown as the mean ± SEM, unless otherwise 
stated, and were statistically analyzed using a 
two-sided Student’s t-test. P＜0.05 was considered 
statistically significant. Kaplan–Meier survival curve, 
HR with 95 % confidence intervals and log-rank P 
value were calculated and plotted in R using 
Bio-conductor packages. 
Study approval 
The study was approved by the ethics committee 
of the Cancer Hospital of Shantou University Medical 
College, and a written informed consent was obtained 
for all patients enrolled in this study. The protocol for 
animal study was approved by the Institutional 
Animal Care and Use Committee of SUMC.  
Results 
Notch3 expression is correlated with the 
luminal epithelial phenotype in breast cancer 
To investigate the potential role of Notch 
signaling in breast cancer, we examined Notch 
expression in breast cancer cell lines. Western blotting 
showed that both full-length (FL) Notch3 and Notch3 
intracellular domain (ICD) were mainly expressed in 
breast cancer cells with a luminal epithelial 
phenotype, as shown by increased ERα and 
E-cadherin expression in MCF-7 and T-47D cell lines 
(Figure 1A). However, Notch3 expression was not 
detected in either basal-like MDA-MB-231 and BT-549 
breast cancer cell lines, or the HER2-positive SK-BR-3 
breast cancer cell line, which expresses the stromal 
cell marker vimentin (Figure 1A). We further detected 
Notch3 and ERα mRNA expression by real-time PCR 
in several breast cancer cell lines. As expected, high 
levels of Notch3 and ERα mRNA were expressed in 
the ERα-positive MCF-7 and T-47D breast cancer cell 
lines, but not in the ERα-negative MDA-MB-231, 
BT-549 and SK-BR-3 breast cancer cell lines (Figure 
1B, C). In contrast, Notch1 and Notch2 were relatively 
highly expressed both in ERα-positive and -negative 
cells, and Notch4 was primarily expressed in 
ERα-negative cells at protein (Figure 1D) and mRNA 
levels (Figure 1E-G). Immunofluorescence further 
revealed that Notch3 was expressed in the 
ERα-positive MCF-7 and T47D cell lines, but not in 
ERα-negative MDA-MB-231 and BT-549 cells (Figure 
1H, Supplementary Figure 1A). Our results, in 
general, suggest a possible link between Notch3 and 
the luminal epithelial phenotype in breast cancer. 






Figure 1. Notch3 expression is associated with the luminal epithelial phenotype in breast cancer in cell lines and clinical cases. (A) Expression of Notch3, ERα, 
and EMT-related markers, such as E-cadherin and vimentin, was detected by western blot in breast cancer cell lines MCF-7, T47D, MDA-MB231, SKBR3 and BT549. (B and C) 
Relative ERα and Notch3 mRNA levels were quantified in breast cancer cell lines by real-time PCR. (D) N1ICD, N2ICD and N4ICD protein levels were detected by western blot 
in breast cancer cell lines. (E, F and G) Notch1, Notch2 and Notch4 mRNA levels were determined by real-time PCR in breast cancer cell lines. (H) Immunofluorescence 
staining for Notch3 and ERα was performed in MCF-7 (upper panel) and T47D (bottom panel) cells, and nuclei were stained with DAPI (4’, 6-diamidino-2-phenylindole). A 
merged image was obtained by combining Notch3, ERα and DAPI fluorescent staining images. The scale bar represents 50 μm. (I) ERα and Notch3 protein expression were 
immunohistochemically stained in ERα-positive (a, b) and ERα-negative (c, d) human breast cancer tissues. 
 
To determine the relationship between Notch3 
and the luminal phenotype in clinically diagnosed 
breast cancer, we examined Notch3 expression 
patterns in human tumor samples from luminal A and 
triple-negative (TNBC) breast cancers. Using 
immunohistochemistry, we observed that Notch3 was 
highly expressed in luminal A compared with TNBC 
tissue (Figure 1I and Supplementary Table S1).  
Notch3 up-regulates ERα expression at the 
protein and mRNA levels 
Because Notch3 was highly expressed in 
ERα-positive breast cancer cells and 
Notch3-expressing cells acquired the characteristics of 
mammary luminal progenitors that give rise to the 
ERα-positive luminal lineage [17, 32, 33], we 
speculated that Notch3 regulates ERα expression in 
breast cancer. To examine this hypothesis, we silenced 
and overexpressed Notch3 in breast cancer cells. As 
expected, downregulation of Notch3 by siRNA 
decreased ERα expression at both the mRNA and 
protein levels in ERα-positive MCF-7 and T47D cells 
(Figure 2A-D). Conversely, overexpression of the 
active form of Notch3, N3ICD, resulted in 
upregulation of ERα at both the mRNA and protein 
levels in ERα-positive MCF-7 and ERα-negative 
MDA-MB-231 cells (Figure 2E-H). 
Immunofluorescence confirmed that Notch3 and ERα 
co-localized in the nuclei of ERα-positive MCF-7 and 
T47D cells, whereas Notch3 silencing also resulted in 
decreased ERα expression (Figure 2I). These results 
suggest that Notch3 up-regulates ERα expression in 
breast cancer cells. 






Figure 2. Knockdown or over-expression of Notch3 down- or up-regulates ERα gene transcription in breast cancer cells. (A and B) ERα-positive 
MCF-7 cells were transiently transfected with 2 different siRNAs against Notch3 (#1 and #2) for 48 h, and then Notch3 and ERα protein and mRNA expression levels 
were detected and quantified by western blot (a) and quantitative real-time PCR (B). (C and D) ERα-positive T47D cells were transiently transfected with 2 different 
siRNAs against Notch3 (#1 and #2) for 48 h, and Notch3 and ERα protein and mRNA expression levels were detected and quantified by western blot (C) and 
quantitative real-time PCR (D). (E and F) Protein (E) or mRNA (F) levels for Notch3 and ERα were determined by western blot or quantitative real-time PCR in 
MCF-7 cells transfected with an N3ICD-expressing or control vector as indicated. (G and D) Protein (G) or mRNA (H) levels for Notch3 and ERα were determined 
by western blot or quantitative real-time PCR in MDA-MB-231 cells transfected with the N3ICD-expressing or control vector as indicated. (I) Confocal fluorescence 
microscopy of DAPI/Notch3/ERα staining in T47D (upper) and MCF-7 (bottom) cells treated with control siRNA or siNotch3. The scale bar represents 50 μm. 





Notch3 activates ERα expression by binding to 
CSL binding elements in the ERα promoter 
To explore the mechanism underlying 
transcriptional regulation of ERα by Notch3, the ERα 
promoter (~1 kb) was cloned into the upstream of a 
luciferase reporter gene, and luciferase activity was 
determined in the absence or presence of the active 
Notch3 (N3ICD). Luciferase activity of the ERα 
promoter was decreased after silencing Notch3 in 
MCF-7 cells (Figure 3A), and was activated in a 
dose-dependent manner by N3ICD overexpression in 
MDA-MB-231 cells (Figure 3B). We identified 2 
CSL-binding motifs located at the upstream 
(-159∽-155bp and -380∽-384bp) of exon 1 in the ERα 
promoter, to which Notch3 can potentially bind 
(Figure 3C). We compared full length ERα promoter 
activity with mutant ERα promoter vectors, 
containing deletions in one (ΔCSL2 construct) or both 
(ΔCSL1&2 construct) CSL binding elements. We 
found that the mutant reporters with either one CSL 
or two CSL deletions showed significantly decreased 
luciferase activities by 50% or 75%, respectively, 
following co-transfection with N3ICD into 
MDA-MB-231 cells (Figure 3C and D). These results 
show that Notch3 up-regulates ERα promoter activity 
through binding to CSL binding elements. 
To examine whether Notch3 binds directly to the 
ERα promoter, we performed chromatin 
immunoprecipitation assays (ChIPs), using antibody 
against Notch3, on MCF-7 cells with IgG as a negative 
control. Two pairs of primers were designed to span 
the CSL binding elements located at the upstream 
(-328 - 90 bp, ERα P1 and -527 - 298 bp, ERα P2) of 
exon 1 in the ERα promoter (Figure 3E). Significant 
binding was observed in the two regions containing 
CSL binding elements, but not in the control region 
(located at -628-386bp), which does not contain CSL 
binding elements (Figure 3F).  
To further investigate the mechanism by which 
Notch3 regulates ERα expression, electrophoretic 
mobility shift assays (EMSAs) were employed to 
analyze core elements in the ERα promoter for Notch3 
binding (Figure 3G), showing that Notch3 binds both 
core elements. Competition assays for Notch3 
binding, using an excess of unlabeled 
oligonucleotides (100×), abolished the Notch3-shift 
band. An excess of unlabeled mutation 
oligonucleotide (TGTCT, 100×) did not compete nor 
abolish the Notch3-shifted band (Figure 3H). The 
supershifted band was noted after an anti-Notch3 
specific antibody and labeled probe were added to 
MCF-7 nuclear extracts, confirming that Notch3 can 
bind to the core element (GGGAA) of the ERα 
promoter. Based on previous reports [34, 35], our 
findings demonstrate that Notch3 binds as part of a 
complex to the ERα promoter. 
Overexpressed N3ICD in MDA-MB-231 cells 
reverses EMT 
Because ERα is a marker of the luminal epithelial 
phenotype in breast cancer cells, we speculated that 
Notch3 regulates the shift of EMT markers. To 
investigate Notch3’s role in EMT regulation, we 
examined the shift in EMT markers after Notch3 
overexpression in MDA-MB-231 cells. As expected, 
overexpressed N3ICD in MDA-MB-231 cells 
downregulated the mesenchymal marker vimentin, 
and upregulated the epithelial cell marker E-cadherin 
(Figure 4A). In two-dimensional cell culture, 
MDA-MB-231-vector-transfected cells had a more 
spindle-shaped, mesenchymal morphology, whereas 
MDA-MB-231 cells stably expressing N3ICD 
exhibited a more epithelial phenotype (Figure 4B). In 
a wound healing assay, MDA-MB-231-control cells 
migrated as single cells to close the wound, whereas 
MDA-MB-231-N3ICD cells migrated as a collective 
sheet. After 24 h, the gap in MDA-MB-231-N3ICD 
cells was 65.5% of the 0 h injury width, which is much 
higher than the 20.5% displayed by 
MDA-MB-231-control cells. This shows that Notch3 
overexpression inhibits cellular motility in 
MDA-MB-231 cells. The inhibitory effect disappeared 
(percentage was reduced to 32.3%) when ERα was 
knocked down by siRNA (Figure 4C-D, 
Supplementary Figure 1B). Cell migration assays 
(transwell) showed fewer MDA-MB-231-N3ICD cells 
migrated at ~30.4% of vector-transfected control cells 
after 48 h. However, when ERα was knocked down by 
siRNA, the number of migrated cells increased more 
than 2-fold compared with MDA-MB-231-N3ICD 
cells. Similar results were observed in a cell invasion 
assay (transwell) (Figure 4E and F). These data 
suggest that Notch3 inhibits the motility and 
invasiveness of MDA-MB-231 cells via upregulation 
of ERα. 
Knock-down of Notch3 in MCF-7 cells 
promotes EMT 
In addition, Notch3 knockdown in MCF-7 cells 
decreased expression of the epithelial cell marker 
E-cadherin compared to control cells. In contrast, 
expression of the mesenchymal marker vimentin was 
increased in MCF-7 cells by silencing Notch3 (Figure 
5A). We also observed morphological changes 
associated with EMT in MCF-7 cells following stable 
Notch3 knockdown. Control cells maintained their 
cobblestone-like phenotype with strong cell-cell 
adhesion, while some cells with Notch3 shRNA had a 
fibroblast-like morphology and showed cellular 





scattering (Figure 5B). We examined the effect of 
Notch3 silencing on cell motility using a wound 
healing assay. After 48 h in cell culture, the gap in 
shNotch3 MCF-7 cells was 35.4% of that at 0 hour 
compared with control transfected shNC MCF-7 cells 
(56.7%), indicating that Notch3 knockdown enhanced 
cellular motility. The residual open gap was back to 
56.1% by transfecting an expression plasmid encoding 
ERα, showing that this change could be rescued by 
ERα overexpression (Figure 5C and D, 
Supplementary Figure 1C). The motility potential of 
Notch3-silenced MCF-7 cells was determined using a 
transwell migration assay. Notch3 shRNA led to a 
5-fold increase in cell migration, which was partially 
rescued by ERα overexpression (Figure 5E and F). 
Similar results also occurred in the cell invasion assay 
(Figure 5G and H). These data suggest that Notch3 
knockdown in MCF-7 cells promotes cellular motility 
and invasiveness via downregulation of ERα. 
Notch3 inhibits breast cancer tumorigenesis 
and metastasis in vivo 
To explore the role of Notch3 in tumorigenesis 
and metastasis in breast cancers, we employed 
MDA-MB-231 cells overexpressing N3ICD or 
Notch3-knockdown MCF-7 cells in tumor xenograft 
models. Orthotopic implantation of MDA-MB-231 
N3ICD or control cells in mammary fat pads was 
followed either by caliper measurement or BLI 
monitoring. After 6 weeks, mice implanted with 
N3ICD-overexpressing MDA-MB-231 cells developed 
fewer xenograft tumors (5/11) that were also smaller 
in size and weighed less than those in the control 
group (9/11), indicating that Notch3 inhibited breast 
cancer tumorigenesis and delayed the onset of breast 
cancer formation (Figure 6A-C). Similarly, BLI 
monitoring showed that mice bearing 
N3ICD-overexpressing MDA-MB-231 tumors 
consistently had an ~100-fold decreased tumor 
burden at 6 weeks after transplantation compared 
with the control group (Figure 6D and E). After 
transplants were harvested, immunohistochemistry 
showed that tumors derived from control cells 
expressed higher levels of vimentin, but that tumors 
derived from Notch3-overexpressing cells expressed 
higher levels of Notch3, ERα and E-cadherin, 
suggesting that the Notch3-mediated shift in 
expression of mesenchymal makers to epithelial 
markers was retained in vivo (Figure 6F). BLI analysis 
of various organs ex vivo showed that livers in 4 out of 
11 mice derived from control cells developed 
metastases, but no metastases were found in livers 
derived from Notch3-overexpressing MDA-MB-231 
cells (Figure 6G and H). These results demonstrate 
that Notch3 inhibits tumorigenesis, shifts 
mesenchymal markers to epithelial markers and 
inhibits breast cancer metastasis in vivo.  
Moreover, we injected MDA-MB-231 cells via tail 
vein to examine whether Notch3 affects breast cancer 
metastasis. Thirty-one days after transplantation of 
N3ICD-overexpressing MDA-MB-231 cells or control 
cells, mice were euthanized and organs were 
harvested. Lung metastases were detected in 5/6 mice 
harboring vector-transfected MDA-MB-231 cells, as 
determined by BLI analysis, while no metastases were 
observed in mice implanted with 
N3ICD-overexpressing cells (n = 6) (Figure 6I and J). 
With ex vivo BLI imaging and HE staining, we further 
confirmed that Notch3 overexpression suppressed 
lung metastasis and vessel invasion in our breast 
cancer model (Figure 6K-N).  
We then investigated whether Notch3 
knockdown in MCF-7 cells increased tumor 
metastasis in vivo. Mock- and Notch3 
shRNA-transfected MCF-7 cells were injected into the 
tail vein of Nu/Nu mice, and formation of tumor 
metastases was allowed to proceed for 8 weeks. As 
shown in Figure 6O, lungs from mice (2/7) injected 
with Notch3-silenced MCF-7 cells displayed breast 
cancer metastasis, whereas lungs from mice injected 
with mock-transfected MCF-7 cells did not (0/9). The 
statistical analysis showed a difference between the 2 
groups (Chi-Square Test, p = 0.074). We did not find 
breast cancer metastasis in the livers from both 
Notch3-silenced and mock-transfected MCF-7 cells. 
These results further demonstrate that Notch3 inhibits 
breast cancer metastasis in vivo.  
Notch3 mRNA is a favorable prognostic factor 
in breast cancer patients 
We further evaluated the prognostic value of low 
or high expression of Notch3 mRNA in a large online 
clinical microarray database of breast tumors from 
4142 patients. Elevated expression of Notch3 mRNA 
in tumor was associated with better recurrence-free 
survival (RFS) (n = 3554, p = 6.7×10-7, HR = 0.75) in all 
breast cancer patients (Figure 7A). In ERα-positive 
subgroup of patients, higher Notch3 expression 
indicated better prognosis with respect to RFS (n = 
2766, p = 8.5×10-5, HR = 0.75) as expected (Figure 7B). 
In the ERα-negative subgroup of patients, who often 
develop metastatic disease and have a poor prognosis, 
elevated expression of Notch3 in tumors was 
associated with longer RFS (n = 788, p = 0.0066, HR = 
0.72) (Figure 7C). When the analysis was restricted to 
the intrinsic subtype of breast cancer, higher 
expression of Notch3 mRNA was found to be 
indicative of favorable prognoses for recurrence-free 
survival in luminal A (n = 1764, p = 0.0026, HR = 0.7), 
luminal B (n = 1002, p = 0.00037, HR = 0.69) and 





basal-like (n = 580, p = 0.0026, HR = 0.66) subtypes 
(Figure 7D-F), but not in the HER-2 overexpressing 
subtype (n = 208, p = 0.53, HR = 0.87). 
 
 
Figure 3. Notch3 regulates ERα expression by binding to CSL binding elements in the ERα promoter. (A) MCF-7 cells, silenced by control siRNA or siNotch3, 
were co-transfected with an ERα promoter-driven firefly luciferase (ERα-Luc) and an internal control plasmid pRL-SV40 expressing Renilla luciferase. Promoter activity was 
expressed as the ratio of firefly luciferase/Renilla luciferase. (B) MDA-MB-231 cells were transiently co-transfected with ERα-Luc and N3ICD at incremental doses as indicated, 
and Renilla luciferase was transfected as an internal control. (C) Schematic representation of wild-type ERα-Luc and mutant constructs ΔCSL (deletion of one CSL binding 
element) or Δ2CSL (deletion of both CSL binding elements) used in reporter assays. (D) Luciferase reporter assay with ERα-Luc or mutant ERα-Luc were performed in the 
absence or presence of N3ICD in MDA-MB-231 cells. Promoter activity was expressed as the ratio of firefly luciferase/Renilla luciferase. (E and F) ChIP assays. Schematic 
representation of the 2 CSL binding element-containing regions (Region 2 and Region 3) and negative control region (Region 1) used in the ChIP assay. PCR products were 
detected in the presence of anti-Notch3 antibody. (G) Sequences of probes 1 and 2 containing the GGGAA core element for EMSA. (H) EMSA using probes 1 and 2. 
Competition assays were performed by adding either 100-fold (lane 3) excess of unlabeled oligonucleotides containing the core CSL binding element, or 100-fold excess of 
unlabeled mutant oligonucleotides in the core CSL binding element (lane 4). Each reporter assay was performed in triplicate. 






Figure 4. N3ICD overexpression in MDA-MB-231 cells reverses EMT. (A) Western blot showing the protein levels of E-cadherin and Vimentin after 
overexpressing N3ICD in MDA-MB-231 cells. (B) Morphology of MDA-MB-231 cells transfected with N3ICD or a control vector, Scale bars represent 50 μm. (C 
and D) Representative images (C) and quantitative (D) wound recovery data after 24 h in MDA-MB-231 cells transfected with N3ICD and ERα siRNA. Scale bars 
represent 50 μm. (E and F) Representative micrographs and quantitative data of Matrigel-coated or non-coated transwell assays. Stably transfected N3ICD 
MDA-MB-231 cells were co-transfected with siERα or siNC. Invading or migrating cells were counted in 5 random fields. Scale bars represent 50 μm. All experiments 
were performed at least three times and data were statistically analyzed by two-sided t-test. *P < 0.05 versus control. Error bars indicate SEM. 
 
Discussion 
In this study, we demonstrate for the first time 
that Notch3 transcriptionally upregulates ERα 
expression and inhibits EMT in breast cancers. In 
breast development, Notch3 expression is highly 
elevated in mammary luminal-restricted 
progenitor/mature luminal cells compared with 
bi-potent mammary stem cells, indicating that Notch3 
might play a crucial role in the regulation of ERα and 
luminal epithelial development [18, 20]. In the present 
study, we found that Notch3 upregulates epithelial 
molecular markers, such as E-cadherin, and silencing 
Notch3 increases mesenchymal biomarkers, such as 
vimentin, in breast cancers.  






Figure 5. Notch3 knockdown in MCF-7 cells promotes EMT. (A) Notch3 knockdown by shRNA in MCF-7 cells downregulated the epithelial cell marker 
E-cadherin and upregulated the mesenchymal cell marker vimentin. (B) Morphology of MCF-7 cells stably transfected with control shRNA and shNotch3. (C and D) 
Wound healing assay showed that Notch3 knockdown enhanced cellular motility in MCF-7 cells; these changes were rescued by transfection with an expression 
plasmid encoding ERα. Representative images (C) and quantitative (D) wound recovery data after 48 h in cell culture. (E-H) Notch3 knockdown increased cellular 
migration and invasion of MCF-7 cells, and these changes were rescued by transfection with an ERα plasmid. Representative images (E and G) and quantitative data 
(F and H) from migration or invasion assays. All experiments were performed at least three times and data were statistically analyzed by a two-sided t-test. *P<0.05 
versus control. Error bars indicate SEM. 






Figure 6. Notch3 reserves EMT, tumorigenesis and metastasis in a humanized mouse model. (A) Control vector or Notch3-expressing MDA-MB-231 
cells (2×106 cells) were injected into the mammary fat pad tissue of immunodeficient NU/NU mice (n=11). Tumor size was measured twice a week. Mice were 
euthanized and examined for metastasis when the primary tumor grew to 1.5 cm in diameter. Mice implanted with either vector (upper panel) or N3ICD transfected 
cells (middle panel) at 42 days after implantation. Primary tumors dissected from each group of mice are shown in the lower panel. (B) The time course of tumor 
growth is shown with error bars representing ±SEM. (C) Weight of primary tumors in the different groups. Error bars show ±SEM. (D) Representative 
bioluminescence imaging and (E) quantitative analysis of imaging was performed. (F) Immunohistochemical staining for Notch3, ERα, and EMT markers, as well as HE 
staining, were performed in dissected tumors. (G) Livers from both control and N3ICD expressing groups ex vivo were imaged with BLI (upper panel), and HE staining 
was also performed (lower panel). (H) Quantitative analysis of liver imaging. (I) 30 days after tail-vein injection with MDA-MB-231 N3ICD or control cells, whole 
body BLI was performed. (J) Quantitative analysis of lung imaging in vivo. (K-L) Lungs from mice injected either with vector-transfected or MDA-MB-231 cells 
expressing N3ICD were imaged with BLI after euthanization. (M) Metastatic lesions were detected with HE staining in lungs from mice with vector control cells (left 
panel) or N3ICD-expressing MDA-MB-231 cells (right panel). (N) HE staining shows blood vessel invasion in lung metastases from vector transfected cells. (O) HE 
staining was applied to detect lung metastases in either vector control (left panel) or Notch3-silenced MCF-7 cells (right panel). 






Figure 7. Kaplan-Meier analysis of the probability of correlation between Notch3 expression and patient survival in a cohort of 4142 human 
breast cancer patients in Kaplan Meier Plotter database. (A) Recurrence-free survival (RFS) in breast cancer patients according to Notch3 expression. (B, C) 
RFS of ER-positive and ER-negative breast cancer patients. (D - G) RFS in luminal A, luminal B, basal-like or Her-2 subtype breast cancer patients. P values were 
computed by log-rank test. 
 
Using a conditional Notch3-induced transgenic 
mouse strain, Lafkas et al. demonstrated that Notch3 
is expressed in highly clonogenic and transiently 
quiescent luminal progenitor cells [33]. When the 
active form of Notch3, N3ICD, is conditionally 
expressed, p21 and p16INK are induced in luminal 
mammary cells [33]. Similarly, N3ICD overexpression 
was found to result in a very significant expansion of 
a sub-set of cells, the CD24highCD29low cell 
subpopulations, which are positive for CK6/CK18 
and reported to contain luminal progenitors [17]. All 
of these findings, together with the present study, 
strongly suggest that Notch3 is most likely a 
biomarker of luminal epithelial cells in breast cancers. 
We show a strong correlation between Notch3 
and ERα both in breast cancer cells and human breast 
cancer tissues. In particular, ectopic overexpression of 
Notch3 results in activation of ERα in ERα-negative 
breast cancer cell lines, whereas silencing Notch3 in 
ERα-positive cells downregulates ERα. In 
ERα-positive breast cancer cells, estrogen/ERα 
signaling has been shown to antagonize 
EMT-promoting transcription factors, such as Slug 
and Snail, and activates MET-promoting factors, such 





as GATA3 and FoxA1 [3]. Taking into consideration 
that loss of ERα might correlate to distant metastasis, 
exploring the role of Notch3 in regulating ERα in 
breast cancer cells would be of significance, e.g., for 
elucidating ERα generation, increasing breast cancer 
therapeutic efficacy and preventing metastasis [36, 
37]. With regard to how ERα is regulated via Notch3, 
our results demonstrate that N3ICD specifically binds 
to CSL binding elements in the ERα promoter and 
transactivates ERα expression. However, the 
mechanisms through which Notch3 transactivates 
ERα, either by specificity of the TAD domain or by 
inducing its ligands, remains unclear. 
 
 
Figure 8. Proposed model of how Notch3 and ERα mediate EMT in breast 
cancer, where the Notch3 ICD complex directly binds to the ERα promoter, 
and ultimately transactivates ERα and its downstream signaling, permitting the 
repression of E-cadherin and up-regulation of vimentin to induce EMT in breast 
cancer. 
 
In addition to the shift from luminal epithelial 
markers to mesenchymal markers, we observed that 
silencing Notch3 drastically promoted the EMT 
phenotype, including migration and invasion in vitro 
and metastasis in vivo, and increased the proportion of 
cancer stem cells in breast cancers (unpublished data). 
In contrast, Notch3 overexpression suppressed EMT 
as well as migration and invasion in ERα-negative 
cells. Notably, ectopic ERα expression significantly 
reversed EMT transition induced by silencing Notch3, 
and conversely, knock-down of ERα almost 
completely reversed MET induced by Notch3 
overexpression. The above observations strongly 
suggest that Notch3, at least in part, inhibits EMT 
through ERα activation/upregulation. Given that 
ERα is an indicator of effective endocrine therapy in 
breast cancers, more extensive studies are needed to 
focus on the relationship between Notch3 status and 
sensitivity/responses to endocrine therapy in both 
ERα-positive and -negative breast cancers. 
In an ERα-negative cell line, Notch3 
overexpression inhibited tumorigenesis and tumor 
growth in an orthotopic mouse model, as determined 
by both caliper measurement and non-invasive 
monitoring with molecular imaging. MDA-MB-231 
cells overexpressing Notch3, after injection via tail 
vein, demonstrated significantly reduced metastasis 
to lungs detected with bioluminescence imaging, 
revealing that metastatic potential was suppressed by 
Notch3. In ex vivo assays, increased luciferase activity 
was detected in resected lungs or livers, consistent 
with the results of in vivo imaging showing the lack of 
metastasis when Notch3-overexpressing cells were 
implanted. We further histologically confirmed liver 
or lung metastases in both orthotopic and tail vein 
models with H&E staining. Moreover, 
immunohistochemical staining demonstrated 
upregulation of ERα expression and epithelial 
biomarkers, suggesting that metastatic inhibition by 
Notch3 overexpression is likely caused via 
modulation of ERα. Although recent reports indicate 
EMT may not be required for invasion and metastasis, 
as evidenced with genetically engineered mouse 
models, EMT is still thought to be important for 
metastasis [38, 39]. In combination with the 
observation that lung metastasis is promoted by 
silencing Notch3, Notch3 might play an important 
role in inhibiting tumorigenesis and metastasis in 
breast cancer through inducing ERα and suppressing 
EMT, at least in part.  
Notch3 high expression detected with 
immunohistochemistry has shown an inconsistent 
prognostic predictive value, e.g., poor prognosis in 
hepatocellular carcinoma, non-small cell lung cancer, 
medullary thyroid cancer, and ovarian cancer [40-44]; 
favorable prognosis in small intestine and gastric 
cancers [24, 45]. In a large clinical microarray 
database, Notch3 transcripts were significantly 
associated with better RFS in clinically diagnosed 
breast cancer patients, especially for those with 
ERα-positive tumors. In terms of sub-type of breast 
cancers, Notch3 did show a favorable RFS in luminal 
type breast cancers, but no association with the Her2 
overexpressed type. However, interestingly, in 
ER-negative or triple-negative subtypes, higher 
expression of Notch3 also predicted more favorable 
prognosis than in those subtypes expressing lower 
Notch3. It seems that Notch3 would be a better 
prognostic value independent of ERα in those 
ER-negative breast cancer patients. Mechanistic 





analysis suggested that Notch3 could function as a 
tumor suppressor by regulating complex signaling 
pathways. For example, our previous studies and a 
study by Cui et al demonstrated that Notch3 functions 
as a tumor suppressor by controlling cellular 
senescence and inhibits breast cancer cell proliferation 
by up-regulating p21[46], by inducing Cdh1 
expression [27], and by activating Kibra-mediated 
Hippo/YAP signaling in breast cancer epithelial cells 
[26]. Taken together, clinical data suggest Notch3’s 
role in predicting recurrence for breast cancer 
patients, in particular, for those with the ERα-positive 
luminal phenotype, supporting the experimentally 
described role for Notch3 as a potential tumor 
suppressor by suppressing EMT through ERα 
activation. Moreover, future determination of Notch3 
at the protein level and its sub-cellular localization 
would provide more insights on its prognostic 
significance. Jaskula-Sztul et al. demonstrated that 
genetic and/or pharmacological induction of Notch3 
had a tumor-suppressor role in medullary thyroid 
carcinoma. AB3, an HDAC inhibitor, induced both 
full length Notch3 and its activated form NICD3, and 
inhibited cellular proliferation by inducing apoptosis 
in MZ-CRC-1 and TT cell lines [47]. Thus, it may be 
useful to explore AB3’s potential as a combined 
therapy option. 
In summary, the present study demonstrates 
that Notch3 suppresses EMT through 
transcriptionally activating ERα expression (Figure 8). 
These findings delineate the role of a Notch3/ERα 
axis in maintaining the luminal phenotype and 
inhibiting tumorigenesis and metastasis in breast 
cancer, providing a novel strategy to re-sensitize ERα 
negative or low expressing breast cancers to hormone 
therapy.  
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